Beam Therapeutics (BEAM) announced that the FDA has granted Regenerative Medicine Advanced Therapy, RMAT, designation to BEAM-302, a liver-targeting lipid-nanoparticle formulation of a guide RNA and an mRNA encoding a base editor designed to correct the disease-causing mutation in patients with alpha-1 antitrypsin deficiency. AATD is an inherited genetic disorder that affects the lungs and/or liver, leading to early onset emphysema and liver disease, and for which there is significant unmet need for effective therapies that can treat the entire spectrum of disease.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Beam Therapeutics: Promising Gene Editing Advancements and Strategic Execution Reinforce Buy Rating
- Beam Therapeutics: Promising Pipeline and Financial Stability Justify Buy Rating
- Beam Therapeutics: Promising Advancements in Base Editing and Strong Financial Position Support Buy Rating
- Beam Therapeutics price target lowered to $55 from $78 at Guggenheim
- Beam Therapeutics price target lowered to $70 from $75 at Wells Fargo